N. Martin

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

J. Forbes, P. Neven, C. Barrios, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P5-11-01: The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up

P. Neven, H. Eidtmann, G. Minckwitz, 2010 .

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

J. Forbes, P. Neven, C. Barrios, 2013 .

S1-3: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST.

P. Neven, H. Eidtmann, R. Coleman, 2011 .